7 active not recruiting, 5 completed, 3 recruiting, 1 not yet recruiting. 17 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Active not recruiting 7, Completed 5, Recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery - Colon Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 60 | 2025-09-01 | 2025-06-13 |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer | Phase 1 / Phase 2 | Recruiting | Nimbus Wadjet, Inc. | 134 | 2025-03-31 | 2026-05-06 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer Prolgolimab - Colorectal Cancer | Phase 2 | Completed | Blokhin's Russian Cancer Research Center | 30 | 2022-03-31 | 2026-04-27 |
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) Capecitabine, Oxaliplatin, Retifanlimab - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 25 | 2021-11-05 | 2024-08-02 |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. Durvalumab, Tremelimumab - Gastric Cancer, Microsatellite Instability | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 31 | 2021-04-01 | 2026-09-11 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination - Gastric Cancer, Colorectal Cancer | Phase 2 | Active not recruiting | Udai Kammula | 20 | 2019-12-03 | 2026-06-01 |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection - Localized Oesogastric Adenocarcimona, MSI and or dMMR | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 32 | 2019-10-23 | 2025-06-15 |
| Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status temozolomide (induction),, pembrolizumab (treatment) - Colorectal Neoplasms, Microsatellite Instability | Phase 2 | Completed | IFOM ETS - The AIRC Institute of Molecular Oncology | 107 | 2019-01-23 | 2026-03-03 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Active not recruiting | ImmunityBio, Inc. | 40 | 2018-12-11 | 2026-01-14 |
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor Nivolumab, Relatlimab - Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2018-11-16 | 2026-10-08 |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Durvalumab, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Withdrawn | University of Washington | 2018-05-15 | 2018-01-17 | |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML - Metastatic Cancer Colorectal | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 57 | 2017-12-04 | 2025-07-23 |
| Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Nivolumab - Carcinoma, Renal Cell, Head and Neck Neoplasm | Phase 2 | Completed | UNICANCER | 269 | 2017-06-16 | 2024-02-28 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) pembrolizumab - Advanced Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 1609 | 2015-12-18 | 2025-09-22 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers MK-3475, INCB024360 - Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 444 | 2014-07-17 | 2022-02-14 |
Colorectal Neoplasms (7) · Stomach Neoplasms (5) · Turcot syndrome (4) · Carcinoma, Merkel Cell (3) · Carcinoma, Renal Cell (3) · Colonic Neoplasms (3) · Endometrial Neoplasms (3) · Head and Neck Neoplasms (3) · Melanoma (3) · Small Cell Lung Carcinoma (3) · Uterine Cervical Neoplasms (3) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2)
Genomic Instability (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11) · Neoplasms (11) · Neoplasms by Site (11) · Gastrointestinal Neoplasms (10) · Colonic Diseases (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Rectal Diseases (7) · Adenocarcinoma (6) · Neoplasms by Histologic Type (6)
Nivolumab (5) · pembrolizumab (5) · durvalumab (3) · Docetaxel (2) · Injections (2) · Ipilimumab (2) · ALT-803 (1) · Capecitabine (1) · Chemotherapy, Adjuvant (1) · Cyclophosphamide (1) · Disulfides (1) · Immunoglobulin G (1) · Irinotecan (1) · Neoadjuvant Therapy (1) · Oxaliplatin (1)
GERCOR - Multidisciplinary Oncology Cooperative Group (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Blokhin's Russian Cancer Research Center (1) · Gruppo Oncologico del Nord-Ovest (1) · IFOM ETS - The AIRC Institute of Molecular Oncology (1) · ImmunityBio, Inc. (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · Marengo Therapeutics, Inc. (1) · Merck Sharp & Dohme LLC (1) · Nimbus Wadjet, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · UNICANCER (1) · Udai Kammula (1) · University of Washington (1)
United States (8) · France (6) · Canada (2) · Italy (2) · Spain (2) · Australia (1) · Ireland (1) · Netherlands (1) · Portugal (1) · Russia (1) · United Kingdom (1)
Anita Scheuber, MD, PhD (1) · Dung Le, MD (1) · Filippo Pietrantonio, MD (1) · Hanneke WM van Laarhoven, MD, PhD (1) · Jan M Prins, MD, PhD (1) · Mark Jones, MD (1) · Michael Schweizer (1) · Salvatore Siena, MD (1) · Sarah Derks (1) · Silvia Marsoni, MD (1) · Udai S Kammula, MD (1)
PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33109741, PMID 33148693, PMID 33836153, PMID 33992635, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35522273, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35791694, PMID 35835611, PMID 35969830, PMID 36748723, PMID 37269904, PMID 39594133, PMID 39637944, PMID 39979665, PMID 40121391, PMID 40340830, PMID 40389373, PMID 41370727, PMID 41920388
2015 (1), 2016 (1), 2018 (1), 2023 (1), P30CA015704 (1), P50CA062924 (1)